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1. Introduction 
It is well established that progression from a pre-malignant to malignant invasive tumor 
phenotype is dependent on angiogenesis1-7. As such, a hallmark of all solid cancers is their 
ability to induce the formation of their own blood supply thereby sustaining their growth and 
is characterized by increases in endothelial cell (EC) proliferation and blood vessel 
heterogeneity8-10.  The ‘angiogenic switch’, is a complex balance of multiple pro- and anti-
angiogenic factors secreted by both host and tumor cells, which when balanced in favor of pro-
angiogenic factors will trigger new vessel formation (Figure 1)1-7. The expression of these pro- 
and anti- angiogenic regulators is dependent on various physiological and pathological factors 
in addition to the tumor type, stage and microenvironment2,8. It has been shown previously 
that although tumor angiogenesis to some extent recapitulates the normal process of 
angiogenesis, it is not well organized and leads to the majority of solid cancers having tortuous 
and dilated vessels that have abnormal physiological function. This commonly leads to 
insufficient blood flow, poor delivery of oxygen and nutrients, inadequate removal of waste, 
increased vessel permeability and tumor edema due to alteration in EC tight junctions and 
contacts2,11-15. These inefficiencies in blood flow result in changes within tumor 
microenvironment that can trigger further expression of a battery of angiogenic factors, setting 
up a continuous cycle of dysfunctional vessel formation1,2,8,9.  The precise mechanisms 
governing expression of pro- or anti-angiogenic factors are still not fully understood. In 
response to oncogene activation and/or metabolic stress, such as that seen in solid tumors, 
tumor cells can directly secrete growth factors including vascular endothelial growth factor 
(VEGF) and Angiopoietin-1 (Ang-1) stimulating the angiogenic switch to enhance vessel 
formation17-23 (Figure 1), or attracting macrophages that can indirectly promote release of 
angiogenic factors10. Multiple candidate factors that signal tumor cells to initiate this cascade 
have been proposed1,2,11-14. The main contributors include hypoxia and increased physical 
forces, both generated in rapidly growing tumors, that disrupt the EC connections within the 
extracellular matrix (ECM), and the products of oncogenes and mutated tumor suppressor 
genes1,2,11-14.  The relative contribution of various angiogenic pathways, their interactions and 
combinatorial impact on tumor angiogenesis is not precisely known and requires further 
characterization in order to establish a comprehensive picture of tumor angiogenesis. 
Principles of anti-angiogenic therapy 
Originally, the knowledge that tumor angiogenesis was vital for solid tumor growth held 
much promise for designing efficacious treatments for cancer, with the hope of arresting 
tumor growth and progression, therefore maintaining a patients health in a stable   
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Fig. 1. The Angiogenic Switch 
A complex balance between pro- and anti- angiogenic factors exists in all 
microenvironments and is instrumental in the enhancement or decrease in vessel formation.  
The main angiogenic factors that have so far been elucidated are listed, not all of their 
mechanisms are fully understood. 
asymptomatic state. Anti-angiogenic cytostatic agents were thought to have several 
advantages over the traditional cytotoxic chemotherapeutic agents7,13,15-18. First, it was 
hypothesized that regardless of the extent of tumor heterogeneity, tumor angiogenesis is a 
non-neoplastic homogenous process; hence anti-angiogenic strategies would be efficacious 
against a variety of human solid cancers. Second, the issue of resistance to chemo- or radiation 
therapy (CT or RT) of tumor cells would not apply to the angiogenic component of a solid 
cancer. Third, the vascular compartment is readily accessible and no interstitial pressure 
would be required to reach the targeted ECs. Fourth, the presence of up-regulated and altered 
EC receptors in tumor vasculature, would permit specific targeting of therapeutic molecules to 
tumor vasculature, while normal blood vessels would not be targeted.  
Overall the results of anti-angiogenic based clinical trials, however, have been somewhat 
disappointing12,19.  With increased understanding and experience using anti-angiogenic 
treatment, certain limitations and causes for failure of anti-angiogenic therapy have come to 
light 8,12,19. One of the principle realizations being that the process of tumor angiogenesis is 
as heterogeneous as tumor cells, and the dynamics of tumor vessel biology alters with 
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tumor type, tumor stage and phase of tumor growth.  Other reasons are that these trials 
have either targeted only one angiogenic pathway, or in several instances the exact anti-
angiogenic mechanism is not known. We therefore need to expand our knowledge of the 
qualitative differences in tumor vessel formation that are specific to each tumor and 
individualize the therapeutic approach. We also need a more detailed understanding of the 
relevant angiogenic regulators in specific tumors, which differ according to tumor 
microenvironment, in order to generate target specific agents for testing in clinical trials 
Additional reasons why there has been some disappointment in the efficacy of translation of 
pre-clinical results to clinical trials include: (1) a lack of appropriate pre-clinical tumor 
models. To date, primarily xenograft models have been used where tumors are grown in an 
ectopic microenvironment in an immune deficient mouse. (2) There has been a lack of end-
points of treatment and surrogate markers of response to anti-angiogenic therapy. To date, 
the primary method for establishing response has been measurement of tumor size in 
xenograft models, extent of EC apoptosis, number of EC progenitor cell (EPC) circulators 
and changes in EC signaling. Dynamic imaging of tumor characteristics in response to 
treatment would be of significant clinical and translational value.  The future direction of 
tumor angiogenesis and anti-angiogenic therapy will focus on designing small animal 
imaging modalities that will best identify the extent of effective and functional blood flow 
within a tumor vascular network and the impact of treatment on the dynamic blood supply 
of a tumor. By establishing these methodologies we can then translate end-points of 
therapeutic response to drug more accurately that can be applied to clinical therapy. 
An important evolution in anti-angiogenic therapy is the use of combinatorial therapy. 
Combinatorial therapy takes advantage of using anti-angiogenic strategies together with RT 
in order to improve the clinical efficacy of both treatment modalities. The principle of 
combinatorial therapy in large part relies on the concept of ‘vascular normalization’, which 
was introduced and popularized primarily by Rakesh Jain over the past decade. Vascular 
normalization states that abnormal pathological tumor vasculature, in response to anti-
angiogenic therapy, becomes normalized and results in a window of opportunity during 
which more efficient tumor blood flow can be delivered to the tumor, improving delivery of 
tumor oxygenation and therapeutics, and ultimately response to RT 20-22. Improvement in 
tissue oxygenation in particular the centre of tumor increases the functionality of RT ad CT 
in the tumor. 
The precise timing of this window of opportunity and extent by which ‘vascular 
normalization’ improves response to RT however remains unknown.  There are some pre-
clinical studies and early clinical trials that have explored the therapeutic benefits of 
combining anti-angiogenesis with RT, but results have been inconsistent34,37-48 and the 
optimal scheduling of these adjuvant treatments has to be established. Moreover, individual 
tumor type plays a significant role in determining the correct combinatorial scheduling and 
very few studies have focused on brain tumors. 
1.1 Normal vessel formation: Vasculogenesis and angiogenesis 
Our understanding of the molecular mechanisms of tumor angiogenesis heavily relies and 
derives from studies of the mechanisms of normal vessel development.  Vascularization is 
critical for embryonal development and normal physiological functions in large multi-
cellular organisms. It is also pivotal for the progression of a multitude of pathological 
processes.6,7,23-27. The primitive vascular network is modified by the process of angiogenesis, 
leading to maturation, branching and formation of a complex vascular network6,7,9,23,28. 
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During physiological angiogenesis new vessels are formed from pre-existing ones via 
sprouting and non-sprouting mechanisms6,7,9,23,28 concomitant with an increased interaction 
between EC and the pericytes (PC) and smooth muscle cells (SMC) of the ECM, creating a 
stabilized vascular network (Figure 2 and 3)9,28. The main organs that are vascularized 
primarily by angiogenesis are mesodermal organs such as the kidney and brain that do not 
contain angioblasts6,7,9,23,28.  In addition to maturation of the vasculature into a complex 
network, determination of vessel fate is also a crucial aspect of normal vessel 
development29,30. Vessel fate was originally thought to be regulated by hemodynamic 
factors such as blood flow, extent of blood oxygenation, blood pressure and alteration in 
other blood and microenvironmental characteristics 29,30. However, recent evidence suggests 
that it is primarily governed by genetic regulation and cytokines such as Ephrins and the 
Notch signaling pathway 29,30. Normal angiogenesis is vital for wound healing and for the 
development of the endometrium during the uterine cycle. Angiogenesis is prevelant in 
pathological conditions such as tumor growth, ischemia, vascular malformations and 
inflammatory reactions however, the process is particularly abberant leading to the  
 
 
Fig. 2. The process of Physiological New Vessel Formation 
A. Angioblasts differentiate to form endothelial cells B. Endothelial cells proliferate to form 
blood islands C. Blood islands coalesce to form hollow lumen vessels or primitive vascular 
tubes that subsequently form a primary vascular network D. Maturation of the vessel leads 
to new vessels sprouting through migration and proliferation of ECs with reassembly into 
new lumens E. The last step in the process of angiogenesis is stabilization of the vessels 
through recruitment of PC and SMC surrounding the vessel.  
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torturous heterogeneic vessels that have come to be associated with tumor vascular 
networks19,31. In some disease processes such as cerebral ischemia the angiogenic response is 
deficient, while in other disease processes, such as tumor angiogenesis or vascular 
malformation, there is excessive angiogenesis resulting in vessels that are abnormal in 
structure and function19,31. 
An alternative pathway for vessel formation is vasculogenesis, a process whereby 
mesenchymal progenitors migrate from the bone marrow (BM) and differentiate into ECs6. 
In turn, mesenchymal derived ECs then proliferate to form a de-novo primitive vascular 
network in an a vascular tissue in the process of in-situ angiogenesis (Figure 3 and 4)6,7,23. 
The main organs that are vascularized by means of vasculogenesis include the heart, great 
vessels, spleen and other endodermal organs6,7,23. Vasculogenesis has long been thought of 
as a pre-natal stage vessel formation occurring exclusively in the developing embryo. 
However, recent data has speculated that neovascularization in adult life, both in 
pathological and physiological conditions, can also occur by vasculogenesis58-61, and is 
particularly prevalent in large-solid cancers62.  
 
 
Fig. 3. Regulators of neo-angiogenesis 
Although not fully understood the various Pro- and Anti- angiogenic factors can be broadly 
linked to specific mechanisms underlying neo-angiogenesis. As there is a high level of 
redundancy within this system many of the factors have multiple functions and multiple 
factors can be involved in each step.  
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Fig. 4. Mechanisms of Tumor Neo-angiogenesis 
Tumor angiogenesis is thought to arise from 4 mechanisms: 
Co-option – the colonization of existing vessels 
Angiogenesis – the branching and colonization of existing vessels 
Vasculogenesis – the formation of new vessels de novo from circulating EC progenitors 
migrating from the bone marrow 
Vascular Mimicry - the newest suggested source of vessels whereby the tumor cells directly 
transdifferentiate into EC forming their own vessels 
Circulating BM-derived endothelial progenitor cells (EPC), the adult counterpart of 
embryonic angioblasts, were first isolated over 15 years ago from the peripheral blood of 
patients with vascular trauma, septic shock, sickle cell anemia and cancer63,64. Accumulating 
evidence indicates that these EPCs can be mobilized from the BM to initiate de novo vessel 
formation in response to oncogenic mediators in solid cancers65-67 6,7,23. When isolated from 
circulation and exposed to angiogenic factors, they formed highly proliferative endothelial-
like colonies63,64. However, there is controversy as to whether these BM derived cells 
(BMDCs) contribute directly to vessel endothelium as ECs or as perivascular cells (PVC) and 
whether this varies with tumor type, growth stage and potentially in response to 
treatment58,63,68-72. A variety of BMDCs have so far been linked to vasculogenesis, however 
conflicting results exist over the degree of these BMDCs influence on the vascular 
endothelium. In particular EPCs73-78, CD11b+ myeloid cells79, Tie2+ monocytes80,81, 
VEGFR1+ hemangiocytes, and tumor associated macrophages (TAM) 82,83 have all been seen 
to come from the BM and incorporate into tumors and their vasculature both directly, 
through generation of endothelium and indirectly, by stabilizing the tumor vasculature 
through localizing around the perivascular regions62-64,84.  
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On the basis of recent studies, it appears that some, but definitely not all, experimental 
tumors and types of ischemia utilize vasculogenesis in generating their blood vessel 
endothelium, emphasizing the need to identify factors that may promote vasculogenesis. 
Once these factors are identified, possible therapeutic applications are numerous, including: 
(1) enhancing the pharmacologic ability to stimulate neovascularization after ischemia or 
disrupt tumor vasculature by targeting all types of vessel formation and (2) a gene therapy 
approach in which BM or EPCs are utilized as cellular delivery vehicles to deliver 
therapeutic genes to ischemic areas or tumors 63,64.  
Alternate mechanisms of tumor neovasculogenesis exist including Co-option, whereby the 
tumor cells will accumulate around existing vessels and colonize the already efficient 
vascular networks. Although less supporting evidence exists, it has also been suggested that 
tumor cells themselves transdifferentiate into EC which are then able to form functional 
vessels in the tumor (Figure 4). 
1.2 Molecular regulators of angiogenesis  
A large number of endogenous pro- and anti-angiogenic factors have been identified 
(Figure 1)1,14,18,19,31 whose signaling pathways interact in a highly complex and coordinated 
manner in order to produce functional vessels (Figure 3). Each angiogenic factor can play 
multiple roles depending on the context in which it is expressed. The regulatory role of each 
molecule is dependent on the microenvironment, the temporal and spatial expression 
profile, and the combinatorial effect of other angiogenic factors32. Additionally, angiogenesis 
is indirectly regulated by many transcriptional factors, oncogenes and tumor suppressor 
genes, which regulate other aspects of cellular function such as proliferation, apoptosis and 
motility1. Among the angiogenic factors identified, there are three groups that are thought to 
have an endothelial specific role, because their receptors are found exclusively on ECs32. 
These three groups are: VEGF, which binds to its receptors VEGFR1/Flt-1 and 
VEGFR2/Flk-1/KDR, Angiopoetins (Ang1 and Ang2), which bind to their receptors 
Tie2/TEK, and the more recently identified EphrinA and EphrinB, which bind to EphA and 
EphB receptors32.  All three classes make a critical contribution to mature vessel formation  
(Figure 3 and 5). 
1.2.1 Pleotropic angiogenic factors 
Several cytokines are direct regulators of angiogenesis in addition to being indirect 
modulators of EC specific factors such as VEGF26,33.  Acidic and Basic Fibroblastic Growth 
Factor (aFGF, bFGF), were amongst the first cytokines implicated closely in angiogenesis26,34. 
FGFs (aFGF and bFGF) induce EC proliferation, migration and tubule formation, in addition 
to providing a mitogenic signal to many other cell types2,26. However, in transgenic knock-
out mice for FGFs vessel development is normal, suggesting a level of redundancy in the 
pathway. Platelet Derived Growth Factor (PDGF) activate their receptors, homo- or hetero-
dimeric complexes of PDGF-or PDGF subunits88-90 (Figure 5). Increased 
expression of PDGF- is noted in these PVC both physiologically and in many solid tumors, 
and activation of PDGF receptors results in proliferation of many cell types including 
astrocytes. Transforming growth factor- (TGF-) is able to regulate EC biology directly, 
affecting proliferation, differentiation, adhesion and apoptosis, and indirectly by 
upregulating VEGF26.  There is speculation that at low doses TGF- stimulates, while at high 
doses it inhibits growth of ECs, with a similar effect on EC tubule formation35,36. 
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Additionally, TGF- is thought to regulate angiogenesis by acting as a chemotactic agent for 
monocytes, fibroblasts and other inflammatory agents important in angiogenesis 26.  
 
 
Fig. 5. Diagrammatic representation of VEGF, PDGF and Ang signaling 
Schematic demonstrates the numerous interactions feasible amongst each signaling family, 
suggestive of the level of redundancy in these pathways determined by the 
microenvironment and so presence of signals and receptors.  
1.2.2 Role of the extracellular matrix in tumor angiogenesis 
Angiogenesis takes place in a complex ECM, which is critical for modulation of EC behavior.  
The ECM is composed of highly organized proteins and proteoglycans, and its composition 
effects EC shape, structure and proliferation, together with EC growth factor expression and 
interactions with blood vessels37. Remodeling of the ECM is a pre-requisite for formation of 
new blood vessels. The basement membrane provides structural support to the vasculature 
and is composed of type IV collagen, laminin and fibronectin38. Proteases such as Matrix 
Metalloproteinases (MMPs), and their tissue inhibitors, (TIMPs), regulate the breakdown of 
ECM and are associated with tissue destruction in many pathologic settings38-40. The relative 
contribution of individual MMPs to vessel formation is not precisely understood, however, 
certain MMPs are thought to have a more specific angiogenic regulatory role, in particular 
MMP-2 (gelatinaseA) and MMP-9 (gelatinaseB) both cleave collagen type IV, fibronectin and 
laminin, the major components of blood vessel basement membrane41. Various 
microenvironmental factors contribute to the regulation of MMPs including direct interactions 
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of angiogenic factors. For instance, bFGF upregulates the expression of the gelatinases (MMP-2 
and MMP-9), whereas VEGF markedly increases only the expression of MMP-242. TIMPs 
tightly regulate the extent of MMPs activity in addition to directly inhibiting endothelial cell 
invasion, proliferation and migration. Therefore, identification of TIMPs holds great potential 
for designing effective anti-angiogenic treatment. 
1.2.3 Role of Endothelial cell specific angiogenic factors 
Vascular Endothelial Growth Factor  
The best-characterized and most extensively studied EC-specific angiogenic factor is Vascular 
Endothelial Growth Factor-A, commonly referred to as VEGF, with the isoform VEGF-165 
being the major secreted isoform and most abundant in human brains27,43. The various 
isoforms, which exist have distinct angiogenic roles, demonstrating organ specificity and 
making unique contributions to vessel development. VEGF through paracrine activation of its 
receptors VEGFR1 (Flt-1), VEGFR2 (Flk-1/KDR) that are predominantly expressed by ECs, 
triggers differentiation of EC precursors, promotes EC survival, mitogenesis and migration 
leading to the formation of tubule structures and neoangiogenesis31 (Figures 3 and 5).  
The critical role of VEGF in vessel development is demonstrated in knock-out mice, where 
deletions of a single allele of the VEGF gene is is embryonic lethal, due to lack of vessel 
formation in addition to deficient blood island formation in the yolk sac44. The biological 
response to VEGF is highly dose dependent, requiring strict control of in vivo VEGF 
expression for normal vessel formation45,46. Over-expression of VEGF in a dose dependent 
manner is also detrimental, leading to abnormal vessels characterized by an attenuated 
compact layer of myocardium, remodeling of the large vessels and tortuous and dilated 
epicardial vessels100,102,103, .  
During adult life, VEGF expression is low to absent in most organs, including the brain, 
other than at sites of physiological neo-angiogenesis33,47,48 however, at sites where new 
vessel formation is required, VEGF is up-regulated. Various regulators of VEGF have been 
identified, the most prominent being hypoxia, which acts to regulate VEGF expression at 
both the transcriptional and post-transcriptional levels49.  
Although hypoxia is the most important physiological regulator of VEGF, other growth 
factors also play a role. Specific cytokines and receptors and their major downstream 
signaling pathways, are usually considered to be important mitogenic regulators, but also 
indirectly regulate expression of VEGF and VEGF receptors. In gliomas, some of these 
cytokine/receptors pathways include activated Epidermal Growth Factor Receptors (EGFR) 
or PDGFR and their signaling pathways such as those mediated by activation of p21-Ras or 
PI3-Kinase33,49,50. In specific, relating to tumor-mediated angiogenesis, VEGF is regulated by 
mutations in oncogenes and tumor suppressor genes, suggesting they act to initially trigger 
the signalling events involved in new vessel formation, thereby supporting further 
proliferation of tumor cells. It has been previously demonstrated that P53 and ras activating 
mutations result in a marked upregulation of VEGF expression. The cross talks between 
mitogenic and angiogenic signals, mediated by VEGF, are of high relevance, particularly in 
solid tumor vascularization.   
Angiopoietins and Tie2/TEK Receptor 
Angiopoietins, (Ang1/2) are important modulators of angiogenesis and are a second class of 
angiogenic factors to have their receptor expressed exclusively on ECs31. The two main 
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family members are Ang1 and Ang2, with their cognate EC specific receptor being 
Tie2/TEK51-53. Ang1 is the activating ligand to Tie2/TEK53, while Ang2 is the naturally 
occurring antagonist (Figure 5). The expression pattern for Ang1 and Ang2, and their 
isoforms, among variable tumor cell lines has been examined and suggests an as of yet 
undetermined role for the different isoforms in pathological scenarios 111,112.  
Early in mouse development, Ang1 is found prominently in the myocardium and 
endocardium whilst later in development, it is primarily seen in the mesenchyme 
surrounding developing vessels, in close in close proximity to ECs53,54. This expression 
pattern suggested that Ang1 plays a role in the development of the heart and vascular 
structures53,54; however, a direct role in angiogenesis was not easily evident, since unlike the 
EC mitogenic signals of VEGF, Ang1 has no direct effect on EC proliferation53,54. Deletion of 
Tie2/TEK caused embryonic lethality due to defects in vascular development, characterized 
by a reduction in EC number, defect in the morphogenesis of microvessels, compromised 
heart development and internal hemorrhage51.  
Ang2 expression was primarily observed in the major vessels such as the dorsal aorta, but 
not in all vascular structures55. In adult life, Ang2 is present at sites of vascular remodeling 
such as in the ovary, placenta, uterus and other areas of active neo-vascularization55. 
Interestingly, transgenic mice over-expressing Ang2 died embryonically with a similar 
phenotype as the Ang1 and Tie2/TEK knock-out mice, suggesting that Ang2 is a natural 
antagonist for Ang1-mediated Tie2/TEK activation in EC, making Tie2/TEK the first known 
naturally occurring receptor tyrosine kinase (RTK) that is so precisely regulated in vivo 55.  
Tie2/TEK expression persists throughout life in the quiescent endothelial cells including 
those in the normal brain, providing continuous stabilizing force to the mature adult 
vasculature through Ang1 activation56,57. Tie2/TEK is critical for normal embryonic vessel 
development and knock-out of Tie2/TEK or ablation with a dominant negative mutant 
causes embryonic lethality58-60. The abnormal vessels are characterized by a reduction in EC 
number and lack of recruitment of PVC58-60.  There is a decrease in sprouting and 
remodeling of the primitive vascular network, leading to restricted growth of the head and 
heart, together with a loss of heart trabeculation58-60. During normal physiological processes 
such as wound healing and pathological angiogenic states such as tumor vascularization, 
Tie2/TEK expression and activation are increased56,57,61,62, indicating a requisite role for this 
pathway in neo-angiogenesis.  
A paradigm incorporating interactions of VEGF and Ang1/2 in the development of normal 
embryonal and adult vasculature has been proposed63. VEGF and VEGFRs are essential for 
the formation of the primitive vascular network, while Ang1/2 and Tie2/TEK interactions 
signal maturation of the primitive vessels63(Figure 3). During normal and pathological 
angiogenesis, a relative increase in Ang2 expression by the ECs inhibits Tie2/TEK 
activation, thereby destabilizing the vessels and sensitizing ECs to VEGF, which results in 
EC proliferation, sprouting and neo-angiogenesis 63. However, this paradigm is an over-
simplification as we are gradually deciphering the multiple areas of EC biology that Angs 
and Tie2/TEK play a role in64-71. Activation of Tie2/TEK by Ang1 modulates EC adhesion, 
motility and survival67-71. Additionally, Ang1/2 play a highly variable role in angiogenesis 
depending on the levels of VEGF expression, and the microenvironmental and tissue 
context in which they are expressed64-69.   
An important factor governing the functional role of Ang1/2 is their interactions with other 
angiogenic factors, with data suggesting that Ang1/2 can have a dual role in angiogenesis 
depending on the context in which they are expressed32. Recent biochemical research has 
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focused on the collaborative functions that exist between Ang1, Ang2 and VEGF72-75. 
Transgenic mice over-expressing Ang1 in cardiac cells demonstrate no increase in 
angiogenesis, which is in contradiction to the findings of increased angiogenesis with Ang1 
over-expression in skin54. Double transgenic mice over-expressing VEGF and Ang1 showed 
restricted angiogenesis and dampening of the potent angiogenic response Seen following 
VEGF signaling 65. These findings highlight a very context specific role for Ang1 and how it 
can play both a positive or negative regulatory roles in normal physiological angiogenesis. 
Similarly, the role of Angs in tumor angiogenesis is proving to be context dependent, as 
demonstrated by our work in astrocytomas, described below.  
Our current understanding of the Tie2/TEK-Ang pathway indicates that these cytokines 
have a multi-faceted role in promoting and maintaining normal vessels.  The regulatory 
effects of Ang1/2 and Tie2/TEK can vary according to the organ and context in which they 
are expressed. Therefore, we postulate that this pathway potentially contributes in a similar 
context-dependent manner to the formation of the abnormal vasculature. 
Ephrins 
Eph receptors together with their EphrinA and EphrinB ligands were first identified in the 
nervous system for their role in neuronal patterning and axonal guidance 76,77. Ephrins and 
Eph receptors are also postulated to play important functions in arterio-venous 
differentiation and maintenance. EphrinB2 is an early marker of arterial EC and the receptor 
EphB4 an early marker of venous EC30,76-78. Mice with a knock-out of EphrinB2 die 
embryonally due to lack of appropriate orchestration of arterial and venous ECs. EphB4 
knock-out mice show similar phenotypic alterations such embryonal lethality with vascular 
changes that are identical to the EphrinB2 knock-out mice 30,76-78. This suggests that EphB4 is 
the most important receptor interacting with EphrinB2 that regulates normal differentiation 
of the arterial and venous system.  Furthermore, most recent evidence indicates that EphB4 
along with Angiopoietin pathway are important not only in physiological but tumor 
vascular patterning 79,80. Specifically it is thought that Ang1 and EphB4 interaction reduces 
the permeability of the tumor vasculature, potentially by altering EC and SMC interaction, 
in other words influencing vessel maturation 80. 
1.3 Role of progenitor cells in tumor angiogenesis  
The paradox of the sensitivity of the vasculature to irradiation and the resistance to RT could 
be resolved if, as postulated, circulating cells outside of the radiation field can re-colonize 
and/or stabilize the tumor vasculature after irradiation, thereby supporting any remaining 
viable tumor cells. This restoration of the vasculature facilitated by BMDCs is observed in 
ischemic normal tissues and in malignant tissues73-75. These BMDCs are also thought to create 
an environment for tumor growth and invasion, and metastasis 77,  (Figure 6). 
Whether EPCs are a true subpopulation of BMDC that are mobilized from the BM versus 
being present mainly in the circulation remains controversial and data supports that there 
may not be a clear distinction between angiogenesis and vasculogensis as traditionally 
proposed. One of the major limitations in the study of EPCs is the lack of exclusive cell-
surface markers for these cells. 
EPCs that are derived from BM can be mobilized during adult life to sites where new vessel 
formation is required81,82. It is also conceivable that they can reside in organs dormantly, 
become activated and differentiate into ECs in response to certain physiological and 
pathological triggers, thereby contributing to angiogenesis. EPCs express markers similar to 
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ECs, such as VEGFR2, Tie2/TEK, CD34, CD146, von Willebrand factor and PECAM83,84. 
Therefore, making a distinction between EC lining the vessel lumen and EPCs present 
within a vessel lumen can be difficult. Though their relative contribution to angiogenesis is 
not clear85 very recent data suggests that EPCs within a specific vessel wall region, localized 
between smooth muscle and adventitial layer, act as a source of EPCs that will then trigger 
neo-vascularization in adult tumors86. The stem cell marker, CD133, with a yet to be 
determined function, stains EPCs83,84. Stem cells are CD133+ /VEGFR2-, but in vitro can be 
induced to become CD133-/VEGFR2+, and behave as a mature EC83,84. Until these recent 
observations it was thought that adult vessel formation relied solely on neo-angiogenesis 
however these recent results suggest that de novo vessel formation by EPCs to be potentially 
possible 86-88. Recent studies using Id1&3 knock-out mice demonstrate an impaired VEGF 
induced EPCs mobilization and tumor vascularisation, suggesting bone marrow derived 
EPCs are incorporated to the vascular structures in both B6RV2 lymphoma and Lewis lung 
carcinoma tumors. The recruitment of EPCs occurs concurrently with myeloid cells, which 
are believed to stabilize the structure of newly formed vessels. 
There is evidence that chemotactic factors expressed by injured tissue recruits hematopoetic 
stem cells and progenitor cells to aid in neoangiogenesis85,89, however, their role and 
mechanism of activation in tumor angiogenesis is not known. The molecular mechanisms of  
 
 
Fig. 6. BMDC recruitment to Tumor 
Using in vivo 2-photon imaging it is possible to watch with time the recruitment of BMDCs 
to the site of tumor growth and ultimately their dynamic integration into the vasculature 
network. BMDCs distribution can be confirmed following end point histology looking at 
sections through the tumor.  
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activation, recruitment and differentiation of EPCs to tumor angiogenesis is beyond the 
scope of this chapter, but this is an exciting new direction for angiogenesis research, which 
will most likely result in significant advances and potentially yield therapeutic strategies for 
tumors. 
1.4 Role of immuno-modulatory cells in tumor angiogenesis  
In addition to EPCs, other subpopulations of BMDCs are thought to contribute to tumor 
neo-vascularization. It is well established that the role of macrophages extends beyond their  
originally recognized role as scavenger cells and as part of inflammatory cells they are 
proposed to play a crucial role in tumor neo-vascularization, though a specific role has not 
been definitively established. Recent studies demonstrate that monocytes derived from the 
bone marrow are recruited from the circulation and migrate into the tumor stroma where 
they differentiate to form macrophages. Several studies have shown tumor-associated 
macrophages (TAM) to promote tumor angiogenesis and metastases90 and extent of TAM 
correlates with increased tumor angiogenesis. These TAMs can in turn promote neo-
vascularization61. To date only a few studies have focused on this area in solid tumors, and 
it has been suggested that a small subpopulation of monocytes expressing an angiogenic 
specific receptor tyrosine kinase, TIE2 expressing Monocyte (TEM), also play a very specific 
role in neo-vascularization of tumors91. TEMs can be distinguished from TAMs by their 
surface markers (CD45,CD11b,TIE2,F4/80) and lack of mature EC cell surface markers 
(VEGF-R2/CD133/CD34)92. Depletion of the TEM population in mice results in altered 
endothelial staining, which indicates a dramatic reduction in vascular structures, suggesting 
that TEMs are important in the process of glioma tumor angiogenesis9㻟. Another key 
subpopulation of BMDCs are BM derived myeloid cells or myeloid-derived suppressor cells 
(CD45/CD11b/Gr-1), which are thought to eventually differentiate into TAM, TEM and 
granuloctyes. The role of myeloid-cells in cancer progression, in particular vascular 
dependent growth, is becoming more recognized, and interest in using them as therapeutic 
targets is increasing as their depletion can prevent tumor recurrence post-RT94. 
Colony-stimulating factor (CSF-1) gene plays a critical role in macrophage growth and 
development. Inhbition of CSF-1 decreases tumor growth95. The paracrine loop signaling 
between macrophages and tumor cells is essential to the ability of tumor cells to invade 
within the primary tumor. TAMs are found to express a range of angiogenic regulating 
factors, most notable of which are epidermal growth factor (EGF), FGF-2, TGF-a and b and 
CSF-196. A few studies have shown macrophages to be a source of EGF, which acts as a 
chemotactic for tumor cells in mammary tumors in vivo and in vitro. Another chemokine 
thought to be involved in macrophage recruitment is CCL2/monocyte chemotactic protein-1 
(MCP-1), synthesized by ECs MCP-1 is seen to increase in both ischemia and malignancy.   
1.5 Role of hypoxia in tumor angiogenesis  
The responses to hypoxic condition are mostly mediated through activation of hypoxia 
inducible factor (HIF-1) and influenced by tumor microenvironment and underlying vessel 
density97. HIF-1 consists of a constituently active subunit, HIF-1┚, and a secondary subunit, 
HIF-1┙, which is not present under normoxia due to ubiquitin-mediated proteolysis. 
Hypoxia inhibits proteolytic degradation of HIF-1, resulting in dimerization with HIF-1 
and activation of many downstream targets through interaction with a 28-base sequence in 
the 5’ promoter region of the gene, termed the Hypoxia Response Element (HRE)98,99.  The 
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critical regulation of HIF-1 by hypoxia is demonstrated during  embryonal development, 
because whereby HIF-1 knock-out embryos die due to vascular defects.  
Hypoxia induces the transcription of many key angiogenic signaling pathways including 
VEGF 100-105, through  increasing the VEGF mRNA stability through binding of several RNA 
binding proteins 100,102,106-109.  
Similarly it has been shown that in a tumor hypoxic environment, the activation of HIF1┙ 
induces Stromal Derived Factor-1 (SDF-1), a mobilizer of BMDCs, in turn recruiting EPCs, 
pericyte progenitor cells (PPCs) and CD45+ myeloid cells to the tumor contributing to 
neovascularisation.  EPCs and PPCs directly contribute in vascular structure whilst myeloid 
cells have been shown to induce the bioavailability of VEGF, thus promoting the angiogenic 
potential of the tumor63.  
In addition to HIF-1┙, a very recent study has identified the distinct upregulation of HIF-2┙ 
gene expression by glioma stem cells (GSCs) in response to hypoxia, potentially explaining 
the increased VEGF expression and highly angiogenic activity of tumors originating from 
GSC110. Therapeutic intervention such as RT will increase the hypoxic level of tumor and 
therefore contribute to the HIF-1 enhancement of the formation of new blood vessels. Kioi et 
al have shown that irradiation increases tumor hypoxic condition, which in turn enhances 
the number of BMDCs, such as myelomonocytes (CD11b+), recruited to the tumor 
environment, implying that vasculogenesis rather than angiogenesis contributes in RT 
induced tumor progression. Through the blockade of SDF-1, a downstream target of HIF1, 
the recruitment of BMDCs EPCs was completely inhibited demonstrating the specificity of 
the recruitment following RT6㻞. 
1.6 Ionizing radiation and its affect on neo-vascularisation  
A more comprehensive knowledge of the molecular mechanisms of angiogenesis in 
response to RT is required to allow more efficient targeting of angiogenic pathways. There is 
experimental evidence demonstrating that RT regulates tumor angiogenesis, both direct and 
indirectly. RT directly modulates EC biology, by inhibiting EC survival and proliferation, 
preventing EC invasion and tube formation and inducing EC apoptosis111,112. Some studies 
have shown a dose dependent response to RT, where at lower doses, RT can promote EC 
proliferation (<10 Gy)113 while at higher doses (> 10 Gy) induce EC apoptosis114,115. EC 
apoptosis is promoted through inhibiting the main signaling pathway regulating EC 
survival, the PI3K/Akt pathway. Therefore, PI3K/Akt has been proposed as a strong 
candidate target for combinatorial therapy with RT116,117. In addition to regulating EC 
biology, RT also directly regulates expression of angiogenic factors and hence tumor 
angiogenesis.  RT upregulates VEGF and VEGFR-2, in turn promoting EC proliferation and 
tumor angiogenesis, and overall tumor growth45,46,111,118,119. Levels of VEGF expression by 
ECs is suggested to be dependent on RT dose and fractionation schedule120,121. Other 
candidate angiogenic factors also found to modulate RT include Ang-1 and bFGF which 
protect ECs against RT damage115,122, while bFGF enhance anti-tumor effect of RT114,123. 
Similarly, PECAM-1 elevation following RT increases anti-tumor effect of IR by 
upregulating vessel thrombosis and promoting anti-angiogenesis124. RT can regulate tumor 
angiogenesis indirectly as well, by generating hypoxia. Hypoxia in turn induces VEGF and 
VEGFR2 upregulation125-127 and tumor angiogenesis. The tumor angiogenic response elicited 
post-RT is considered as a potential ‘escape mechanism’ that might provide an opportunity 
for tumor cells to avoid radiation cell kill and facilitates cancer recurrence. It is conceivable 
that inhibition of VEGF and other relevant angiogenic cytokines will eliminate the 
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angiogenic survival response post-RT, radiosensitizing ECs and potentiating the benefits of 
RT. The above results are supported to an extent by recent in vivo studies120,121,123,128, 
however, unfortunately clinical trials involving combination of RT and anti-VEGF therapy 
have not proven beneficial, suggesting other mechanisms regulating tumor neo-
vascularization in response to RT may be involved 34,37,39,48. 
Recent evidence has demonstrated the specific migration and recruitment of BMDCs to the 
site of radiation specifically, although negates the process of differentiation following 
integration. The BMDCs instead are retained at the site of RT until a secondary signal, such 
as an oncogenic signal initiates their differentiation, possibly providing a vascular escape 
mechanism for the RT. The molecular mechanisms that regulate BMDC to site of cranial 
irradiation remains to be identified and their potential to be harnessed towards a 
therapeutic benefit further elucidated. 
2.  Abbreviations 
EC – Endothelial Cell 
VEGF – Vascular Endothelial Growth Factor 
Ang 1&2 – Angiopoietin 1 & 2 
ECM – Extracellular Matrix 
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EPC – Endothelial Progenitor Cell 
PC – Pericyte 
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BM – Bone Marrow 
BMDC  - Bone Marrow Derived Cell 
PVC – Perivascular Cell 
TAM  - Tumor Associated Macrophage 
GSC – Glioma stem Cells 
PPC – Pericyte Progenitor Cells 
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